Autolus Therapeutics plc (6A3A.F)
Frankfurt · EUR · Healthcare · Biotechnology
€1.35 (+0.00%) as of
Key statistics
- Market cap
- 359.32M
- Forward P/E
- -0.73
- EPS (TTM)
- -0.9100
- Dividend yield
- 0.00%
- 52-week range
- 1.0400 – 2.1600
- Beta
- 2.14
- Revenue (TTM)
- 117.39M
- Profit margin
- -238.65%
- Volume
- 500.00
About Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- London, United Kingdom
- Employees
- 752
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.